Santen Pharmaceutical

www.santeninc.com/
SEARCH FILTERS
Time filter
Source Type

Patent
Santen Pharmaceutical | Date: 2017-08-30

The purpose of the present invention is to provide an intraocular lens injector with which the tip side of a plunger can be finely formed while ensuring rigidity, and with which the occurrence of shaft deviation during contact with an intraocular lens can be effectively inhibited. A plunger (3) of this intraocular lens injector (1) is provided with: a tip-side shaft part (35) provided with an L-shaped section (36); a central shaft part (33) which is formed flat, and which is wider than the tip-side shaft part (35); and a part (40) to be restricted which is formed from the tip-side shaft part (35) to the central shaft part (33), and which protrudes from the flat surface at the central shaft part (33). Furthermore, an opening (70) in a main body (2) is provided with: a central opening (71) which is open in accordance with the shape of the central shaft part (33); and a restriction part (72) formed so as to protrude from the end surface of the central opening (71), in the thickness direction of the central shaft part (33), in accordance with the shape of the part (40) to be restricted. The part (40) to be restricted has a length in the axial direction which is set such that the part (40) to be restricted is restricted by the restriction part (72) in an interval from an initial position before the L-shaped section (36) begins to be in contact with a second lens support part (93) of an intraocular lens (90), to a position in which the L-shaped section (36) is in contact with the second lens support part (93).


Patent
Santen Pharmaceutical | Date: 2017-08-30

Provided is an eye drop container having superior identifying power. The eye drop container includes an identifying indicium comprising a shape, a pattern, a color or combination thereof imparted to a lateral face of a container body, and a further identifying indicium identical or similar to the identifying indicium imparted to a lateral face of a cap part which is detachably attached to a dispensing mouth of the container body, the indicia making it possible to identify the unity of the container body and the cap part. The container is packaged by a sealing label that renders these identifying indicia visible when the cap part is attached to the container body.


Patent
Santen Pharmaceutical | Date: 2017-04-05

Provided are a therapeutic agent and a prophylactic agent for keratoconjunctive disorder, each agent comprising sacran. A therapeutic agent or a prophylactic agent for keratoconjunctive disorder, each agent comprising sacran.


Patent
Santen Pharmaceutical | Date: 2016-09-01

Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are ophthalmic formulations that deliver a variety of therapeutic agents, including but not limited to rapamycin (sirolimus), analogs thereof (rapalogs) or other mTOR inhibitors, to a subject for an extended period of time. The ophthalmic formulations may be placed in an aqueous medium of a subject, including but not limited to intraocular or periocular administration, or placement proximate to a site of a disease or condition to be treated in a subject. A method may be used to administer a therapeutic agent to treat or prevent age-related macular degeneration, macular edema, diabetic retinopathy, uveitis, dry eye, or a hyperpermeability disease in a subject.


The objective of the present invention is to provide a new medicinal use of clarithromycin. The present invention is a therapeutic agent or a preventive agent for meibomian gland dysfunction or meibomian gland blockage and comprises clarithromycin as an active ingredient. The dosage form is preferably an eye drop or eye ointment.


Patent
Santen Pharmaceutical and Asahi Glass Co. | Date: 2017-08-16

The present invention relates to an ophthalmic aqueous solution for treating ocular hypertension and glaucoma, comprising tafluprost as an active ingredient, nonionic surfactant, stabilizing agent and substantially no preservatives in a single dose or unit dose container consisting essentially of polyethylene.


Patent
Santen Pharmaceutical | Date: 2015-07-13

Provided are a therapeutic agent and a prophylactic agent for keratoconjunctive disorder, each agent comprising sacran. A therapeutic agent or a prophylactic agent for keratoconjunctive disorder, each agent comprising sacran.


Patent
Santen Pharmaceutical | Date: 2017-05-24

The present invention relates to a prophylactic or therapeutic agent for a posterior ocular disease, which comprises a compound represented by formula (1) below:


In the course of developing 2-[[[2-[(hydroxyacetyl) amino]-4-pyridinyl] methyl] thio]-N-[4-(trifluoromethoxy) phenyl]-3-pyridinecarboxamide (compound A), there are the multiple problems: 1) compound A or its salt is difficult to be recrystallized, the storage stability largely differs depending on the kind of the salt, and it is very difficult to obtain a salt of compound A having excellent storage stability; 2) in a crystallization process of compound A, it is very difficult to control a crystal polymorph, and 3) compound A (free body) causes mineral deposition in the stomach when it is orally administered repeatedly. For solving these problems, we made examination focusing on the kind of the salt and, as a result, found that 1) benzenesulfonate of compound A does not decompose by light, humidity and other factors in a 1-week preliminary stability test (severe test), and has no problem in its storage stability, 2) a method of selectively producing two kinds of crystal forms of benzenesulfonate of compound A, and that 3) no mineral deposition in the stomach is observed even after a 4-week repeated oral administration.


Patent
Santen Pharmaceutical and Daiichi Sankyo | Date: 2017-09-13

An ophthalmic aqueous composition comprises levofloxacin, a salt thereof, or a solvate thereof; dexamethasone, an ester thereof, or a salt thereof; and one or at least two isotonic agents. The ophthalmic aqueous composition is substantially free of sodium chloride. This ophthalmic aqueous composition is excellent in drug stability and drug migration and has a clear appearance.

Loading Santen Pharmaceutical collaborators
Loading Santen Pharmaceutical collaborators